TY - JOUR
T1 - Mobile health (mHealth) interventions in prostate cancer survivorship
T2 - a scoping review
AU - Ogunsanya, Motolani E.
AU - Sifat, Munjireen
AU - Bamidele, Olufikayo O.
AU - Ezenwankwo, Elochukwu F.
AU - Clifton, Shari
AU - Ton, Chelsea
AU - Knight, Jennifer M.
AU - Odedina, Folakemi T.
AU - Greer, Joseph A.
AU - Dwyer, Kathleen
AU - Kendzor, Darla E.
N1 - Funding Information:
This research was primarily supported by National Institute on Minority Health and Health Disparities (NIMHD) grant R25MD011564 (to MO). Partial support was additionally provided by Oklahoma Tobacco Settlement Endowment Trust (TSET) grant R22-02, and National Cancer Institute (NCI) Cancer Center Support Grant P30CA225520 awarded to the Stephenson Cancer Center.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023
Y1 - 2023
N2 - Purpose: This scoping review explores the application of mHealth technology in prostate cancer (CaP) management along the survivorship continuum. Methods: The scoping review was conducted using the five-step framework developed by Arksey and O'Malley. Using predefined criteria, we screened citations from Embase, EBSCOHost, Cochrane Library, PubMed, ProQuest, SCOPUS, and Web of Science for primary studies published before December 2021. We selected studies that explored the application of mHealth technology in CaP management and survivorship. Evidence from 14 eligible studies was summarized using narrative synthesis. Results: Fourteen studies published between 2015 and 2021 were included. Ten mHealth apps were identified with only one still in use. Most apps were explored for their supportive care roles during radiotherapy (n = 9) and androgen deprivation therapy (ADT) (n = 1) treatment, mainly to assess outcomes (n = 1) and manage patient-reported symptoms (n = 5). One study deployed mHealth to facilitate recovery after surgery. Very few studies (n = 3) applied mHealth for lifestyle management (i.e., physical activity). Barriers to app usage included connectivity issues, end-user familiarity with the app, login hurdles, and time constraints. Facilitators of app usage included apps being downloaded for participants, devices provided for participants, and the ability to connect with providers through the platform. Conclusions and implications for cancer survivors: The improving survival rates from CaP suggest that men are now living longer with unfavorable treatment side effects such as reduced sexual functioning, pain, and fatigue. Hence, mHealth represents new hope in men’s illness trajectory. However, current application in patients’ care pathways remains poor, particularly in the active phase of CaP management. Efforts must be accelerated to explore individual and healthcare-level drivers of mHealth use. The feasibility and descriptive nature of current studies point to a lack of attention to actual implementation and scale-up issues in research considering mHealth application in CaP, hence accounting partly for the gap in research/practice.
AB - Purpose: This scoping review explores the application of mHealth technology in prostate cancer (CaP) management along the survivorship continuum. Methods: The scoping review was conducted using the five-step framework developed by Arksey and O'Malley. Using predefined criteria, we screened citations from Embase, EBSCOHost, Cochrane Library, PubMed, ProQuest, SCOPUS, and Web of Science for primary studies published before December 2021. We selected studies that explored the application of mHealth technology in CaP management and survivorship. Evidence from 14 eligible studies was summarized using narrative synthesis. Results: Fourteen studies published between 2015 and 2021 were included. Ten mHealth apps were identified with only one still in use. Most apps were explored for their supportive care roles during radiotherapy (n = 9) and androgen deprivation therapy (ADT) (n = 1) treatment, mainly to assess outcomes (n = 1) and manage patient-reported symptoms (n = 5). One study deployed mHealth to facilitate recovery after surgery. Very few studies (n = 3) applied mHealth for lifestyle management (i.e., physical activity). Barriers to app usage included connectivity issues, end-user familiarity with the app, login hurdles, and time constraints. Facilitators of app usage included apps being downloaded for participants, devices provided for participants, and the ability to connect with providers through the platform. Conclusions and implications for cancer survivors: The improving survival rates from CaP suggest that men are now living longer with unfavorable treatment side effects such as reduced sexual functioning, pain, and fatigue. Hence, mHealth represents new hope in men’s illness trajectory. However, current application in patients’ care pathways remains poor, particularly in the active phase of CaP management. Efforts must be accelerated to explore individual and healthcare-level drivers of mHealth use. The feasibility and descriptive nature of current studies point to a lack of attention to actual implementation and scale-up issues in research considering mHealth application in CaP, hence accounting partly for the gap in research/practice.
UR - http://www.scopus.com/inward/record.url?scp=85145983150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145983150&partnerID=8YFLogxK
U2 - 10.1007/s11764-022-01328-3
DO - 10.1007/s11764-022-01328-3
M3 - Review article
AN - SCOPUS:85145983150
SN - 1932-2259
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
ER -